title: Pre-registration efficacy study of a novel marker vaccine against classical swine fever on maternally derived antibody positive (MDA+) target animals.
abstract: Maternally Derived Antibodies (MDA) can have a negative effect on the efficacy of live attenuated vaccines against classical swine fever (CSF). For this reason, a marker vaccine candidate CP7_E2alf was tested for its efficacy in the presence of MDA. Pregnant sows were vaccinated four weeks before farrowing with CSF virus (CSFV) strain "Thiverval". A total of 40 piglets with MDAs were included in this study. At six weeks of age the piglets were allocated into three treatment groups using generalized randomized block design (GRBD) blocking on serological status and pen location. Of the 40 piglets with MDAs, 30 piglets were vaccinated either orally (n = 15) or intramuscularly (n = 15) with a single dose of vaccine candidate produced under Good Laboratory Practice (GLP) conditions. The ten remaining piglets were allocated into the untreated control group. All 40 piglets were oronasally challenged with 2 ml of the highly virulent CSFV strain "Koslov" 14 days after vaccination. It was revealed that presence of MDAs negatively influences the efficacy of the live marker vaccine candidate, however, the extent of this negative impact depends on the route of vaccine administration. Based on our observations, intramuscular vaccination is recommended during CSF control programs in order to develop superior immune protection.
authors.affiliation: National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary. Electronic address: farsanga@nebih.gov.hu.
authors.forename: A
authors.initials: A
authors.lastname: Farsang
authors.affiliation: National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary.
authors.forename: R
authors.initials: R
authors.lastname: Lévai
authors.affiliation: National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary.
authors.forename: T
authors.initials: T
authors.lastname: Barna
authors.affiliation: National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary.
authors.forename: K
authors.initials: K
authors.lastname: Fábián
authors.affiliation: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Blome
authors.affiliation: National Veterinary Institute, Uppsala, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Belák
authors.affiliation: National Food Chain Safety Office, Veterinary Diagnostic Directorate, Budapest, Hungary.
authors.forename: Á
authors.initials: Á
authors.lastname: Bálint
authors.affiliation: CODA-CERVA, Veterinary and Agrochemical Research Centre, Ukkel, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Koenen
authors.affiliation: National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Kulcsár
mesh_terms: D000818:Animals; D015415:Biomarkers; D006691:Classical Swine Fever / Q000276:immunology / Q000517:prevention & control; D005260:Female; D008297:Male; D008431:Maternal-Fetal Exchange / Q000276:immunology*; D011247:Pregnancy; D013552:Swine / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000494:pharmacology*
chemical_list: D015415:Biomarkers; D014765:Viral Vaccines
keywords: CSFV; Classical swine fever; DIVA; European pharmacopoeia; MDA+; Marker vaccine